2Seventy Bio Inc
NASDAQ:TSVT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.92
6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
2Seventy Bio Inc
2Seventy Bio Inc
Net Income (Common)
2Seventy Bio Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
2Seventy Bio Inc
NASDAQ:TSVT
|
Net Income (Common)
-$217.6m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$5.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$126m
|
CAGR 3-Years
-74%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-35%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$4.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
-$479.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
1%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4.7B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
17%
|
CAGR 10-Years
30%
|
|
2Seventy Bio Inc
Glance View
2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 437 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. The company is advancing multiple preclinical and clinical programs in oncology. The firm's lead preclinical programs in B cell non-Hodgkin's lymphoma (B-NHL) and acute myeloid leukemia are illustrations of its multiplex approach applied to address the specific challenges of treating those cancers. The company is developing bbT369 product candidate as a treatment for patients with B-NHL.
See Also
What is 2Seventy Bio Inc's Net Income (Common)?
Net Income (Common)
-217.6m
USD
Based on the financial report for Dec 31, 2023, 2Seventy Bio Inc's Net Income (Common) amounts to -217.6m USD.
What is 2Seventy Bio Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-2%
Over the last year, the Net Income (Common) growth was 14%. The average annual Net Income (Common) growth rates for 2Seventy Bio Inc have been -22% over the past three years , -2% over the past five years .
You don't have any saved screeners yet